Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $5.7 million.

  • ARS Pharmaceuticals' Share-based Compensation rose 5842.38% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 6432.39%. This contributed to the annual value of $14.5 million for FY2024, which is 5737.95% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Share-based Compensation stood at $5.7 million, which was up 5842.38% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Share-based Compensation ranged from a high of $5.7 million in Q3 2025 and a low of -$11.2 million during Q4 2021
  • Moreover, its 5-year median value for Share-based Compensation was $3.4 million (2024), whereas its average is $2.6 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Share-based Compensation crashed by 9383.9% in 2022, and later skyrocketed by 75227.27% in 2023.
  • ARS Pharmaceuticals' Share-based Compensation (Quarter) stood at -$11.2 million in 2021, then soared by 142.51% to $4.8 million in 2022, then tumbled by 52.17% to $2.3 million in 2023, then skyrocketed by 87.14% to $4.3 million in 2024, then soared by 33.45% to $5.7 million in 2025.
  • Its last three reported values are $5.7 million in Q3 2025, $5.4 million for Q2 2025, and $5.3 million during Q1 2025.